Abstract
The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren´t mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
Keywords: Irinotecan, Colon cancer, Autophagy, p53, Chemotherapy, Autophagic cell death, Apoptosis, Bax, Lysosomes, Mitochondria.
Anti-Cancer Agents in Medicinal Chemistry
Title:The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells
Volume: 13 Issue: 5
Author(s): Stanislav John, Jan Mls, Miroslav Cervinka and Emil Rudolf
Affiliation:
Keywords: Irinotecan, Colon cancer, Autophagy, p53, Chemotherapy, Autophagic cell death, Apoptosis, Bax, Lysosomes, Mitochondria.
Abstract: The roles of autophagic cell death and apoptosis induced by topoisomerase inhibitor irinotecan in colon cancer cells with deleted p53 were investigated during 48 h. We report that irinotecan-dependent cytotoxicity and proapoptotic activity were reduced in the present model while autophagy levels significantly increased. Upon p53 transfection, cell demise rates increased, with cells bearing the features of apoptosis and autophagic cell death. The subsequent studies into mechanisms of cell death process revealed the important role of Bax in mediating mitochondrial and lysosomal leakage which might serve as leading signals for both apoptosis and autophagic cell death. These results suggest that different modes of cell death in p53 null colon cancer cells treated with cytostatics (irinotecan) may be activated simultaneously. Moreover, their interactions possibly occur at several stages and aren´t mutually exclusive. This might thus lead to a potential synergism with interesting therapeutic ramifications.
Export Options
About this article
Cite this article as:
John Stanislav, Mls Jan, Cervinka Miroslav and Rudolf Emil, The Role of Autophagic Cell Death and Apoptosis in Irinotecan-treated p53 Null Colon Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1871520611313050015
DOI https://dx.doi.org/10.2174/1871520611313050015 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Synthesis for Acacetin, Chrysoeriol, Diosmetin, Tricin and Other Hydroxylated Flavones by Modified Baker-Venkataraman Transformation
Letters in Organic Chemistry Cancer Stem-Cells Patents in the Context of their Therapeutic Purposes: Exploring the Latest Trends (2011-2015)
Recent Patents on Regenerative Medicine Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Functional Genomics Approaches in Cancer Research
Current Genomics From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8
Anti-Cancer Agents in Medicinal Chemistry Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Integrated Therapeutic Approaches in Head and Neck Cancer: The Importance of Multidisciplinary Team Management
Anti-Cancer Agents in Medicinal Chemistry Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Bioactives in Disease Prevention and Health Promotion: Exploiting Combinatorial Effects
Current Bioactive Compounds Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry